HGEN Humanigen, Inc. Stock Quote

HGEN [NASD]

Index	-	P/E	-	EPS (ttm)	-3.36	Insider Own	28.15%	Shs Outstand	52.66M	Perf Week	-1.23%
Market Cap	991.54M	Forward P/E	3.92	EPS next Y	4.11	Insider Trans	-18.46%	Shs Float	45.29M	Perf Month	-7.25%
Income	-152.60M	PEG	-	EPS next Q	-0.61	Inst Own	39.10%	Short Float	16.55%	Perf Quarter	-16.30%
Sales	0.80M	P/S	1239.43	EPS this Y	-426.20%	Inst Trans	1.11%	Short Ratio	5.85	Perf Half Y	-10.24%
Book/sh	0.32	P/B	50.38	EPS next Y	30.69%	ROA	-202.30%	Target Price	-	Perf Year	-29.30%
Cash/sh	1.51	P/C	10.67	EPS next 5Y	12.50%	ROE	-356.10%	52W Range	7.50 - 29.20	Perf YTD	-7.89%
Dividend	-	P/FCF	-	EPS past 5Y	43.70%	ROI	-193.80%	52W High	-44.79%	Beta	-2.34
Dividend %	-	Quick Ratio	1.90	Sales past 5Y	-	Gross Margin	-	52W Low	114.93%	ATR	0.87
Employees	10	Current Ratio	1.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	40.33	Volatility	4.56% 5.57%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.91	Prev Close	16.58
Shortable	Yes	LT Debt/Eq	1.44	Earnings	-	Payout	-	Avg Volume	1.28M	Price	16.12
Recom	1.80	SMA20	-3.54%	SMA50	-12.27%	SMA200	-1.22%	Volume	1,166,036	Change	-2.77%

Jun-11-21

Initiated

Credit Suisse

Outperform

$28

May-07-21

Initiated

Oppenheimer

Outperform

$30

Feb-23-21

Initiated

JP Morgan

Neutral

$21

Dec-23-20

Initiated

National Securities

Buy

$35

Dec-22-20

Initiated

Jefferies

Buy

$27

Oct-21-20

Initiated

Cantor Fitzgerald

Overweight

$25

Oct-14-20

Initiated

H.C. Wainwright

Buy

$31

Oct-01-20

Initiated

ROTH Capital

Buy

$25

Jul-30-21 11:06AM	NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19 Business Wire
Jul-26-21 08:00AM	Ensysce Biosciences Bolsters Management Team with Appointments of David J. Kovacs as VP Public Policy and David Tanzer as VP Strategic Development GlobeNewswire
Jul-22-21 09:59AM	Humanigens Partner in South Korea Receives Ministry of Food and Drug Safety (MFDS) Approval to Conduct Phase 1 Study of Lenzilumab Business Wire
Jul-13-21 06:51PM	Humanigen: Covid-19 Drug Has Good Odds for EUA Approval, Says Analyst TipRanks
Jul-12-21 08:40AM	Is the Options Market Predicting a Spike in Humanigen (HGEN) Stock? Zacks
Jul-09-21 06:30AM	UKs MHRA accepts Humanigens submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review Business Wire
Jun-28-21 11:46AM	Humanigen Inc. Added to Russell 3000(R) Index Newsfile
Jun-25-21 02:27AM	What Is The Ownership Structure Like For Humanigen, Inc. (NASDAQ:HGEN)? Simply Wall St.
Jun-14-21 06:30AM	Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdoms Medicines and Healthcare Products Regulatory Agency (MHRA) Business Wire
Jun-07-21 08:00AM	Humanigen Announces Ken Trbovich Appointed as Senior Vice President, Investor Relations Business Wire +11.30%
Jun-03-21 08:00AM	Humanigen to Present at the 2021 LD Micro Invitational XI Business Wire -5.79%
May-28-21 09:00AM	Humanigen Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19 Business Wire -11.04%
May-26-21 08:30AM	GM-CSF Gene-Edited CAR-T Data to be Presented at International Society for Cell & Gene Therapy Annual Meeting 2021 Business Wire +8.35%
May-19-21 07:00AM	Humanigen to Present at Jefferies Healthcare Conference Business Wire
May-17-21 08:00AM	Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab Business Wire +6.03%
May-13-21 04:01PM	Humanigen Reports First Quarter 2021 Financial Results Business Wire
10:15AM	Are Options Traders Betting on a Big Move in Humanigen (HGEN) Stock? Zacks
May-11-21 04:19AM	Calculating The Intrinsic Value Of Humanigen, Inc. (NASDAQ:HGEN) Simply Wall St.
May-05-21 11:53AM	Humanigen Announces Publication of Results From Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating the Efficacy and Safety of Lenzilumab in Hospitalized COVID-19 Patients Business Wire +5.43%
Apr-21-21 07:00AM	Humanigen Appoints Dr. Adrian Kilcoyne to the role of Chief Medical Officer Business Wire +10.71%
Apr-19-21 07:00AM	Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study Business Wire -5.70%
Apr-09-21 08:19AM	Humanigen Announces Positive Results From Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme Business Wire
08:02AM	Is the Options Market Predicting a Spike in Humanigen (HGEN) Stock? Zacks
Apr-06-21 02:02PM	Humanigen Announces Closing of Public Offering of Common Stock Business Wire
Mar-30-21 08:08PM	Humanigen Announces Pricing of Public Offering of Five Million Shares of Common Stock Business Wire
Mar-29-21 04:11PM	Humanigen Announces Proposed Public Offering of Five Million Shares of Common Stock Business Wire +54.47%
07:00AM	Humanigen Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19 Business Wire
06:00AM	Humanigen to Host Conference Call to Report Phase 3 Topline Results of LenzilumabTM in Patients Hospitalized With COVID-19 Business Wire
Mar-19-21 07:00AM	Humanigen Sets Date for Virtual Annual Shareholders Meeting Business Wire -5.64%
Mar-12-21 01:30AM	Humanigen, Inc. (NASDAQ:HGEN) On The Verge Of Breaking Even Simply Wall St.
Mar-10-21 04:01PM	Humanigen Announces $80 Million Loan Facility from Hercules Capital Business Wire
04:00PM	Humanigen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update Business Wire
Mar-08-21 08:34AM	Do Options Traders Know Something About Humanigen (HGEN) Stock We Don't? Zacks +5.85%
Mar-05-21 04:32PM	Humanigen to Present at Roth Conference Business Wire
Mar-02-21 07:00AM	Humanigen Expands its anti-GM-CSF Patent Portfolio Business Wire
Feb-25-21 07:30AM	Humanigen to Present at Multiple Investor Conferences in March Business Wire -6.54%
Feb-11-21 07:30AM	Humanigen to Present and Participate at Multiple Upcoming Investor and Industry Conferences Business Wire
Feb-08-21 07:00AM	Humanigen Elects Dr. Dale Chappell to Board of Directors Business Wire
Feb-04-21 02:37PM	IBD 50 Stocks To Watch: Emergent BioSolutions, A Biotech Stock With Solid Biodefense Cred Investor's Business Daily +6.79%
Feb-03-21 07:00AM	Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing Business Wire
Jan-29-21 07:00AM	Humanigen Completes Enrollment in Phase 3 Study of Lenzilumab in Hospitalized Patients with COVID-19 Business Wire
Jan-27-21 07:00AM	Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study PR Newswire
07:00AM	Ajinomoto Bio-Pharma Services and Humanigen Expand Manufacturing Agreement to Support Fill Finish for Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion of Phase 3 Study Business Wire
Jan-25-21 01:21PM	Humanigen signs manufacturing deal with Emergent for experimental COVID-19 drug MarketWatch
08:30AM	Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab Business Wire
Jan-22-21 07:00AM	Humanigen Announces the Addition of BARDA and Expansion of CRADA with the U.S. Government to Develop Lenzilumab for COVID-19 Business Wire
Jan-10-21 08:00AM	Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19 Business Wire
Jan-05-21 04:30PM	Humanigen to Present at Multiple Upcoming Investor Conferences Business Wire +5.57%
Dec-28-20 07:00AM	Humanigen Secures U.S. Patent for Lenzilumab in Preventing Cytokine Storm and Neurotoxicity Related to CAR-T Cell Therapy Business Wire -21.14%
Dec-20-20 03:40AM	What Type Of Shareholders Own The Most Number of Humanigen, Inc. (NASDAQ:HGEN) Shares? Simply Wall St.
Dec-17-20 08:00AM	Humanigen to Present at J.P. Morgan Healthcare Conference Business Wire +23.81%
07:00AM	Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme Business Wire
Dec-14-20 08:00AM	Humanigen to Present at Upcoming Investor Conferences Business Wire +26.29%
Dec-02-20 11:33PM	Is Humanigen, Inc. (HGEN) A Good Stock To Buy? Insider Monkey
Nov-23-20 04:05PM	Humanigen Australia Proprietary Limited Established to Facilitate Asia-Pacific Growth Plans Business Wire
Nov-11-20 07:00AM	Humanigen Reports Third Quarter and Nine Months Ended September 30, 2020 Financial Results Business Wire
Nov-06-20 09:59AM	Humanigen Spikes 13% On Positive Covid-19 Data For Lenzilumab SmarterAnalyst
08:52AM	Is a Surprise Coming for Humanigen (HGEN) This Earnings Season? Zacks
07:00AM	Humanigen Announces Positive Interim Phase 3 Data of Lenzilumab in Patients Hospitalized with COVID-19 Business Wire
07:00AM	Humanigen Announces Cooperative Research and Development Agreement with the Department of Defense to Develop Lenzilumab for COVID-19 Business Wire
Nov-04-20 04:05PM	Humanigen Announces ZUMA-19 Abstract Accepted for Presentation at American Society of Hematology 2020 Annual Meeting Business Wire
Nov-03-20 09:01AM	Humanigen Inks First Asia Licensing Deal For Its Covid-19 Treatment SmarterAnalyst
07:30AM	Humanigen Executes Licensing Agreement for Lenzilumab in COVID-19 with KPM Tech/Telcon RF Pharmaceutical for South Korea and the Philippines Business Wire
Nov-01-20 05:58AM	Humanigen Treats First Patient in Late-Stage COVID-19 Trial SmarterAnalyst
Oct-30-20 02:05PM	Humanigen Announces First Patient Dosed at MedStar Washington Hospital Center in Phase 3 Clinical Study of Lenzilumab in COVID-19 Business Wire
Oct-29-20 07:00AM	Humanigen Announces First Patient Dosed in NIH ACTIV-5/Big Effect Trial Evaluating Lenzilumab for COVID-19 Business Wire -9.13%
Oct-27-20 04:01PM	Humanigen to Present at Upcoming Investor Conferences Business Wire -9.63%
Oct-13-20 12:48PM	NIH to test AbbVie, Boehringer Ingelheim drug in combination with remdesivr MarketWatch
11:00AM	National Institutes of Health Launches its ACTIV-5 "Big Effect Trial" Evaluating Humanigens Lenzilumab as Potential COVID-19 Therapy Business Wire
Oct-05-20 10:20AM	Humanigen's stock soars in active trading after upbeat report on lenzilumab in severe COVID-19 MarketWatch +23.25%
Oct-02-20 08:00AM	Humanigen Announces COVID-19 Case Report Demonstrating Rapid Resolution and Discharge after Single IND Emergency Use Authorization of Lenzilumab Business Wire
08:00AM	Humanigen Announces COVID-19 Case Report Demonstrating Rapid Resolution and Discharge after Single IND Emergency Use Authorization of Lenzilumab(TM) ACCESSWIRE
07:00AM	Humanigen Announces Lenzilumab in COVID-19 Program Updates Business Wire
07:00AM	Humanigen Announces Lenzilumab in COVID-19 Program Updates ACCESSWIRE
Sep-23-20 07:30AM	Humanigen Announces Thermo Fisher Partnership to Expand Manufacturing for COVID-19 Therapeutic Candidate Lenzilumab ACCESSWIRE
07:00AM	Humanigen Announces Thermo Fisher Partnership to Expand Manufacturing for COVID-19 Therapeutic Candidate Lenzilumab Business Wire
Sep-22-20 04:50PM	Humanigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit ACCESSWIRE -6.41%
04:30PM	Humanigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Business Wire
02:25PM	Humanigen Announces Closing of Public Offering of Common Stock ACCESSWIRE
02:00PM	Humanigen Announces Closing of Public Offering of Common Stock Business Wire
Sep-21-20 12:02PM	Will Humanigen (NASDAQ:HGEN) Spend Its Cash Wisely? Simply Wall St. +14.72%
Sep-17-20 09:10PM	Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol HGEN ACCESSWIRE +15.56%
08:30PM	Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol "HGEN" Business Wire
Sep-15-20 07:30AM	Humanigen Announces Proposed Public Offering of Common Stock and Subsequent Listing on NASDAQ ACCESSWIRE
01:00AM	Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen's COVID-19 Therapeutic Candidate Lenzilumab ACCESSWIRE
Sep-14-20 07:00AM	Humanigen Announces Review of Lenzilumab Phase 3 Study in COVID-19 by Data Safety Monitoring Board Business Wire
Sep-04-20 05:00PM	Humanigen Announces One-for-Five Reverse Stock Split; Reverse Split Facilitates Potential Uplisting to Nasdaq ACCESSWIRE -8.91%
04:30PM	Humanigen Announces One-for-Five Reverse Stock Split Business Wire
Sep-02-20 06:21PM	LD Micro 360 Companies --Set to Present this Week. ACCESSWIRE -7.06%
08:00AM	Humanigen to Present at Upcoming Investor Conferences Business Wire
Sep-01-20 06:15PM	Humanigen to Host Investor KOL Conference Call ACCESSWIRE

Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that has completed Phase I clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is based in Burlingame, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chappell Dale	Chief Scientific Officer	Jul 29	Sale	17.03	29,394	500,703	884,029	Jul 30 09:01 PM
Chappell Dale	Chief Scientific Officer	Jul 28	Sale	17.04	9,692	165,162	886,233	Jul 30 09:01 PM
Chappell Dale	Chief Scientific Officer	Jul 23	Sale	17.04	5,584	95,155	886,960	Jul 23 08:32 PM
Chappell Dale	Chief Scientific Officer	Jul 22	Sale	17.04	178,005	3,032,796	887,379	Jul 23 08:32 PM
Chappell Dale	Chief Scientific Officer	Jul 21	Sale	17.14	132,764	2,275,124	900,729	Jul 23 08:32 PM
Chappell Dale	Chief Scientific Officer	Jul 14	Sale	17.06	15,177	258,847	910,686	Jul 16 08:28 PM
Chappell Dale	Chief Scientific Officer	Jul 09	Sale	17.37	296,036	5,142,767	911,824	Jul 09 09:01 PM
Chappell Dale	Chief Scientific Officer	Jul 08	Sale	17.17	48,010	824,111	934,027	Jul 09 09:01 PM
Chappell Dale	Chief Scientific Officer	Jun 25	Sale	17.80	1,000,000	17,803,500	972,361	Jun 25 09:01 PM
Chappell Dale	Chief Scientific Officer	Jun 24	Sale	18.37	139,529	2,563,831	1,047,361	Jun 25 09:01 PM
Chappell Dale	Chief Scientific Officer	Jun 23	Sale	18.28	133,126	2,434,182	1,057,826	Jun 25 09:01 PM
Chappell Dale	Chief Scientific Officer	Jun 18	Sale	18.50	402,480	7,445,558	1,067,811	Jun 21 08:57 PM
Chappell Dale	Chief Scientific Officer	Jun 17	Sale	19.17	181,423	3,478,441	1,097,997	Jun 21 08:57 PM
Chappell Dale	Chief Scientific Officer	Jun 16	Sale	19.41	158,486	3,076,187	1,111,604	Jun 21 08:57 PM
Durrant Cameron	Chief Executive Officer	Jun 14	Sale	20.64	81,441	1,680,934	30,000	Jun 16 09:40 PM
Jordan Edward P.	Chief Commercial Officer	Jun 08	Option Exercise	9.65	14,700	141,855	14,700	Jun 09 05:10 PM
Jordan Edward P.	Chief Commercial Officer	Jun 08	Sale	20.08	14,700	295,176	0	Jun 09 05:10 PM
Chappell Dale	Chief Scientific Officer	Jun 07	Sale	19.08	80,636	1,538,793	1,124,334	Jun 09 04:45 PM
Chappell Dale	Chief Scientific Officer	Jun 04	Sale	18.46	127,084	2,346,415	1,137,066	Jun 04 06:07 PM
Chappell Dale	Chief Scientific Officer	Jun 03	Sale	18.37	191,154	3,511,308	1,157,132	Jun 04 06:07 PM
Chappell Dale	Chief Scientific Officer	Jun 02	Sale	19.01	76,126	1,447,269	1,187,314	Jun 04 06:07 PM
NOMIS BAY LTD.	10% Owner	Mar 11	Sale	16.02	119,201	1,909,672	5,380,799	Mar 11 08:24 PM
NOMIS BAY LTD.	10% Owner	Mar 10	Sale	16.46	32,469	534,589	5,500,000	Mar 11 08:24 PM
NOMIS BAY LTD.	10% Owner	Mar 09	Sale	17.24	83,568	1,440,495	55,632,469	Mar 11 08:24 PM
NOMIS BAY LTD.	10% Owner	Mar 01	Sale	18.65	14,100	262,951	5,616,037	Mar 01 05:48 PM
NOMIS BAY LTD.	10% Owner	Feb 26	Sale	19.18	30,003	575,437	5,630,137	Mar 01 05:48 PM
NOMIS BAY LTD.	10% Owner	Feb 25	Sale	19.17	2,402	46,045	5,660,140	Mar 01 05:48 PM
NOMIS BAY LTD.	10% Owner	Feb 24	Sale	19.55	25,906	506,333	5,662,542	Feb 24 06:27 PM
NOMIS BAY LTD.	10% Owner	Feb 22	Sale	23.21	77,314	1,794,690	5,688,448	Feb 24 06:27 PM
NOMIS BAY LTD.	10% Owner	Feb 19	Sale	23.50	37,300	876,364	5,765,762	Feb 19 06:02 PM
NOMIS BAY LTD.	10% Owner	Feb 18	Sale	21.70	42,408	920,042	5,803,062	Feb 19 06:02 PM
NOMIS BAY LTD.	10% Owner	Feb 17	Sale	19.92	9,700	193,214	5,845,470	Feb 19 06:02 PM
NOMIS BAY LTD.	10% Owner	Feb 13	Sale	19.68	16,423	323,221	5,855,170	Feb 16 06:53 PM
NOMIS BAY LTD.	10% Owner	Feb 11	Sale	21.01	550	11,555	5,871,593	Feb 16 06:53 PM
NOMIS BAY LTD.	10% Owner	Feb 10	Sale	21.39	10,875	232,605	5,872,143	Feb 10 06:04 PM
NOMIS BAY LTD.	10% Owner	Feb 09	Sale	22.32	25,666	572,942	5,883,018	Feb 10 06:04 PM
NOMIS BAY LTD.	10% Owner	Feb 08	Sale	20.70	17,732	367,035	5,908,684	Feb 10 06:04 PM
NOMIS BAY LTD.	10% Owner	Feb 04	Sale	21.88	47,862	1,047,077	5,926,416	Feb 04 06:28 PM
NOMIS BAY LTD.	10% Owner	Feb 03	Sale	19.23	25,000	480,825	5,974,278	Feb 04 06:28 PM
NOMIS BAY LTD.	10% Owner	Feb 02	Sale	20.03	722	14,461	5,999,278	Feb 04 06:28 PM
NOMIS BAY LTD.	10% Owner	Jan 25	Sale	19.23	23,140	445,028	6,070,000	Jan 27 06:04 AM
NOMIS BAY LTD.	10% Owner	Jan 22	Sale	20.08	71,892	1,443,304	6,093,140	Jan 27 06:04 AM
NOMIS BAY LTD.	10% Owner	Jan 20	Sale	18.37	2,500	45,928	6,165,032	Jan 21 09:00 PM
NOMIS BAY LTD.	10% Owner	Jan 19	Sale	21.08	6,000	126,495	6,167,532	Jan 21 09:00 PM
NOMIS BAY LTD.	10% Owner	Jan 19	Sale	19.81	50,000	990,500	6,173,532	Jan 19 06:35 PM
NOMIS BAY LTD.	10% Owner	Jan 15	Sale	18.23	30,000	546,870	6,223,532	Jan 19 06:35 PM
NOMIS BAY LTD.	10% Owner	Jan 14	Sale	18.07	25,000	451,650	6,253,532	Jan 19 06:35 PM
NOMIS BAY LTD.	10% Owner	Jan 12	Sale	18.43	14,577	268,613	6,278,532	Jan 13 05:22 PM
NOMIS BAY LTD.	10% Owner	Jan 11	Sale	19.00	10,423	198,037	6,293,109	Jan 13 05:22 PM
NOMIS BAY LTD.	10% Owner	Dec 28	Sale	22.20	500	11,101	6,303,532	Dec 31 04:30 PM
NOMIS BAY LTD.	10% Owner	Dec 24	Sale	22.05	8,401	185,234	6,304,032	Dec 28 05:17 PM
NOMIS BAY LTD.	10% Owner	Dec 23	Sale	21.09	45,000	948,870	6,312,433	Dec 28 05:17 PM
NOMIS BAY LTD.	10% Owner	Dec 22	Sale	20.00	50,000	1,000,000	6,357,433	Dec 23 04:06 PM
NOMIS BAY LTD.	10% Owner	Dec 21	Sale	19.46	25,000	486,445	6,407,433	Dec 23 09:17 AM
NOMIS BAY LTD.	10% Owner	Dec 18	Sale	15.76	62,700	988,321	6,469,733	Dec 23 09:17 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience